Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4577468
Max Phase: Preclinical
Molecular Formula: C25H18ClN5O2
Molecular Weight: 455.91
Molecule Type: Unknown
Associated Items:
ID: ALA4577468
Max Phase: Preclinical
Molecular Formula: C25H18ClN5O2
Molecular Weight: 455.91
Molecule Type: Unknown
Associated Items:
Canonical SMILES: O=C(O)c1ccc(CNc2ccc(-c3ccc(-c4nc5cc(Cl)ccc5[nH]4)cn3)cn2)cc1
Standard InChI: InChI=1S/C25H18ClN5O2/c26-19-7-9-21-22(11-19)31-24(30-21)18-5-8-20(27-14-18)17-6-10-23(29-13-17)28-12-15-1-3-16(4-2-15)25(32)33/h1-11,13-14H,12H2,(H,28,29)(H,30,31)(H,32,33)
Standard InChI Key: KMRKVWIQPVPEED-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 455.91 | Molecular Weight (Monoisotopic): 455.1149 | AlogP: 5.65 | #Rotatable Bonds: 6 |
Polar Surface Area: 103.79 | Molecular Species: ACID | HBA: 5 | HBD: 3 |
#RO5 Violations: 1 | HBA (Lipinski): 7 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 3.98 | CX Basic pKa: 5.74 | CX LogP: 3.32 | CX LogD: 1.99 |
Aromatic Rings: 5 | Heavy Atoms: 33 | QED Weighted: 0.31 | Np Likeness Score: -1.34 |
1. Yu Y, Wu Z, Shi ZC, He S, Lai Z, Cernak TA, Vachal P, Liu M, Liu J, Hong Q, Jian T, Guiadeen D, Krikorian A, Sperbeck DM, Verras A, Sonatore LM, Murphy BA, Wiltsie J, Chung CC, Gorski JN, Liu J, Xiao J, Wolff M, Tong SX, Madeira M, Karanam BV, Shen DM, Balkovec JM, De Vita RJ, Pinto S, Nargund RP.. (2019) Accelerating the discovery of DGAT1 inhibitors through the application of parallel medicinal chemistry (PMC)., 29 (11): [PMID:30952592] [10.1016/j.bmcl.2019.03.039] |
Source(1):